Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving sunitinib malate works in treating patients with
iodine-refractory recurrent or metastatic thyroid cancer. Sunitinib malate may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking
blood flow to the tumor